Valuation: Amphastar Pharmaceuticals, Inc.

Market Cap 865M 757M 697M 647M 1.23B 82.48B 1.25B 8.35B 3.25B 40.49B 3.25B 3.18B 140B P/E 2026 *
14.6x
P/E 2027 * 11.1x
Enterprise Value 1.18B 1.03B 948M 880M 1.67B 112B 1.69B 11.35B 4.42B 55.03B 4.41B 4.32B 191B EV / Sales 2026 *
1.58x
EV / Sales 2027 * 1.33x
Free-Float
50.3%
Yield 2026 *
-
Yield 2027 * -
1 day-0.15%
1 week-5.31%
Current month-2.82%
1 month-0.66%
3 months-4.71%
6 months-29.00%
Current year-26.77%
1 week 19.08
Extreme 19.08
20.54
1 month 18.22
Extreme 18.22
22
Current year 16.64
Extreme 16.645
29.52
1 year 16.64
Extreme 16.645
31.26
3 years 16.64
Extreme 16.645
67.66
5 years 16.64
Extreme 16.645
67.66
10 years 12.05
Extreme 12.05
67.66
Manager TitleAgeSince
Chief Executive Officer 79 28/02/1996
Chief Operating Officer 76 28/02/1996
Director of Finance/CFO 58 31/03/2014
Director TitleAgeSince
Chairman 76 28/02/1996
Director/Board Member 79 28/02/1996
Director/Board Member 58 03/08/2022
Date Insider Type Main position Quantity % Market Cap.
06-01Tax

Director

-769 0.0017%
05-31Free

Director

25,508 0.0579%
05-31Free

Director

25,508 0.0579%
Change 5-day change 1-year change 3-year change Capi.($)
-0.15%-5.31%-15.47%-65.70% 865M
-1.14%-2.43%+53.72%+159.07% 1,070B
-1.41%+0.32%+66.23%+60.48% 624B
-2.42%+0.18%+34.59%+85.62% 450B
-0.35%+0.53%+31.00%+25.82% 328B
+2.08%+2.06%+40.83%+42.33% 292B
+1.14%-0.14%+29.49%+48.86% 284B
+2.54%+4.43%-25.53%-38.82% 217B
-2.06%+1.63%+22.87%+64.34% 198B
-1.26%+2.60%+15.98%+70.00% 161B
Average +0.96%+0.30%+25.37%+45.20% 362.52B
Weighted average by Cap. +1.31%+0.77%+40.39%+81.85%

Financials

2026 *2027 *
Net sales 744M 652M 600M 557M 1.06B 70.97B 1.07B 7.18B 2.8B 34.84B 2.79B 2.73B 121B 778M 682M 628M 583M 1.11B 74.25B 1.12B 7.52B 2.93B 36.45B 2.92B 2.86B 126B
Net income 64M 56.05M 51.63M 47.92M 91M 6.1B 92.23M 618M 241M 3B 240M 235M 10.39B 84M 73.57M 67.76M 62.9M 119M 8.01B 121M 811M 316M 3.93B 315M 309M 13.64B
Net Debt 311M 272M 251M 233M 442M 29.64B 448M 3B 1.17B 14.55B 1.17B 1.14B 50.45B 173M 152M 140M 130M 247M 16.54B 250M 1.67B 652M 8.12B 651M 637M 28.15B
Logo Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
Employees
1,976
Date Price Change Volume
06/07/26 US$19.61 -0.15% 313,781
02/07/26 US$19.64 -2.29% 315,753
01/07/26 US$20.10 -0.40% 422,109
30/06/26 US$20.18 -2.56% 400,207
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
19.61USD
Average target price
22.00USD
Spread / Average Target
+12.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AMPH Stock